West Pharmaceutical
655 hedge funds and large institutions have $20.6B invested in West Pharmaceutical in 2022 Q2 according to their latest regulatory filings, with 61 funds opening new positions, 227 increasing their positions, 271 reducing their positions, and 110 closing their positions.
59% more call options, than puts
Call options by funds: $64.2M | Put options by funds: $40.4M
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
3.21% less ownership
Funds ownership: 95.1% → 91.88% (-3.2%)
9% less funds holding
Funds holding: 717 → 655 (-62)
16% less repeat investments, than reductions
Existing positions increased: 227 | Existing positions reduced: 271
27% less capital invested
Capital invested by funds: $28.2B → $20.6B (-$7.64B)
45% less first-time investments, than exits
New positions opened: 61 | Existing positions closed: 110
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$209M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$100M |
| 3 |
Morgan Stanley
New York
|
+$84.2M |
| 4 |
DCP
Durable Capital Partners
Bethesda,
Maryland
|
+$80M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$71.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIAS
CFS Investment Advisory Services
Totowa,
New Jersey
|
-$503M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$221M |
| 3 |
WCM Investment Management
Laguna Beach,
California
|
-$138M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$84.7M |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
-$67.4M |
WST Hedge Fund Activity: Q2 2022 in Review
655 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q2 2022, worth a combined $20.6B — down 27% from $28.2B a quarter earlier.
Sellers outnumbered buyers: 110 funds closed out of WST and 61 opened new positions — a net loss of 49 holders — while 271 trimmed existing stakes and 227 added.
The largest buyer was Bank of New York Mellon, adding an estimated $209M. The largest seller was CFS Investment Advisory Services, cutting an estimated $503M.
- 655 institutional investors held West Pharmaceutical (WST) as of Q2 2022, down from 717 in Q1 2022.
- Funds reported $20.6B of West Pharmaceutical stock for Q2 2022, down 27% quarter-over-quarter.
- 61 funds opened new West Pharmaceutical positions in Q2 2022 and 110 closed out, a net change of -49 holders.
- The largest West Pharmaceutical buyer in Q2 2022 was Bank of New York Mellon, an estimated $209M added.
- The largest West Pharmaceutical seller in Q2 2022 was CFS Investment Advisory Services, an estimated $503M sold.
Based on aggregated 13F filings for Q2 2022.